Greehey CCRI News & Events Archive

Filter results


 

Raushan Kurmasheva, PhD, Part of Dmitri Ivanov, PhD, CPRIT Grant Team “Identifying and Optimizing Small Molecules for Drug Development.

September 8, 2020

SOURCE: UT Health San Antonio Newsroom “The following are the additional researchers and their awards: Dmitri Ivanov, PhD, associate professor of biochemistry and structural biology, will receive an Individual Investigator Research Award for Cancer in …


Nucleic Acids Research: “PCAT: an Integrated Portal for Genomic and Preclinical Testing Data of Pediatric Cancer Patient-Derived Xenograft Models” in Oxford Academic (multiple faculty and researchers)

September 8, 2020

Juechen Yang, Qilin Li, Nighat Noureen (Greehey CCRI, Zheng Lab), Yanbing Fang, Raushan Kurmasheva (Greehey CCRI, Kurmasheva Lab), Peter J Houghton (Greehey CCRI, Houghton Lab), Xiaojing Wang (Greehey CCRI, Wang Lab), Siyuan Zheng (Greehey CCRI, Zheng …


Physician’s Weekly: PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.

August 20, 2020

Although cancer is the leading cause of disease-related mortality in children, the relative rarity of pediatric cancers poses a significant challenge for developing novel therapeutics to further improve prognosis. Patient-derived xenograft (PDX) models …


Dr. Raushan Kurmasheva, JCM Guest Editor, invites you to submit research articles, review articles as well as short communications for the Special Issue “The Current Treatment of Childhood Cancer”, by November 30, 2020.

July 6, 2020

 


Clinical Cancer Research: Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

June 1, 2020

Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcom A. Smith, and Peter J. Houghton Abstract Purpose: Vincristine combined with camptothecin derivatives showe …


Raushan Kurmasheva, Ph. D.

Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma (Kurmasheva Lab)

Paige Baldwin1,  Rostislav Likhotvorik2,  Nabeela Baig2,  Jodie Cropper2,  Ruth Carlson2,  Raushan Kurmasheva2,3*† and  Srinivas Sridhar1,4,5*† The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a me …


Springer: Prospective use of the single-mouse experimental design for the evaluation of PLX038A

January 11, 2020

Samson Ghilu, Qilin Li, Shaun D. Fontaine, Daniel V. Santi, Raushan T. Kurmasheva, Siyuan Zheng & Peter J. Houghton Abstract Purpose Defining robust criteria for drug activity in preclinical studies allows for fewer animals per treatment group, and …


Frontiers in Oncology: Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

December 17, 2019

The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both …


SCITECH EUROPA: Preclinical Drug Development for Childhood Cancers

December 2, 2019


Cell Reports: Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

November 5, 2019

Author links open overlay panelJo LynneRokita123  Komal S.Rathi23  Maria F.Cardenas4  Kristen A.Upton1  JoyJayaseelan4  Katherine L.Cross5  JacobPfeil6  Laura E.Egolf17  Gregory P.Way8  AlvinFarrel2  Nathan M.Kendsersky19  KhushbuPatel2  Krutika S.Gaon …